Pérez R.
138
Coauthors
13
Documentos
Volumen de publicaciones por año
Cargando gráfico
| Año de publicación | Num. Publicaciones |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 1 |
| 2007 | 3 |
| 2010 | 1 |
| 2011 | 2 |
| 2013 | 1 |
| 2014 | 1 |
Publicaciones por áreas de conocimiento
Cargando gráfico
| Área de conocimiento | Num. Publicaciones |
|---|---|
| Cáncer | 16 |
| Inmunología | 6 |
| Farmacología | 3 |
| Descubrimiento de fármacos | 1 |
| Biotecnología | 1 |
| Bioquímica | 1 |
| Ensayo clínico | 1 |
Publicaciones por áreas temáticas
Cargando gráfico
| Área temática | Num. Publicaciones |
|---|---|
| Enfermedades | 15 |
| Farmacología y terapéutica | 8 |
| Medicina y salud | 3 |
| Fisiología humana | 1 |
| Fisiología y materias afines | 1 |
| Bioquímica | 1 |
| Microorganismos, hongos y algas | 1 |
Principales fuentes de datos
| Origen | Num. Publicaciones |
|---|---|
| Scopus | 13 |
| Google Scholar | 0 |
| RRAAE | 0 |
Cargando gráfico
Coautores destacados por número de publicaciones
| Coautor | Num. Publicaciones |
|---|---|
| Tania Crombet | 10 |
| De La Torre A.V. | 4 |
| Vázquez A.M. | 4 |
| Carmen Elena Viada | 3 |
| Macías A.E. | 3 |
| Moreno E. | 3 |
| Neninger Vinageras E. | 3 |
| Iznaga N. | 3 |
| Torres F. | 3 |
| Torres O. | 3 |
Cargando gráfico
Top Keywords
Cargando gráfico
Publicaciones del autor
Antiproliferative, antiangiogenic and proapoptotic activity of H-R3: A humanized anti-EGFR antibody
ArticleAbstract: The epidermal growth factor receptor (EGFR) proto-oncogene is frequently overexpressed in tumors ofPalabras claves:Angiogenesis, Epidermal growth factor receptor (EGFR), H-R3, Monoclonal antibody, Signal inhibitorsAutores:Pérez R., Rak J., Tania Crombet, Viloria-Petit A.Fuentes:scopusA view on EGFR-targeted therapies from the oncogene-addiction perspective
ArticleAbstract: Tumor cell growth and survival can often be impaired by inactivating a single oncogen - a phenomenonPalabras claves:CETUXIMAB, Combination therapy, eGFR, Erlotinib, nimotuzumab, Oncogene addiction, Targeted therapyAutores:de Leon J., Moreno E., Pérez R., Tania CrombetFuentes:scopusEGFR-targeting as a biological therapy: Understanding Nimotuzumab's clinical effects
ReviewAbstract: Current clinical trials of epidermal growth factor receptor (EGFR)-targeted therapies are mostly guiPalabras claves:biological therapy, Cancer treatment, eGFR, nimotuzumab, Targeted therapyAutores:Garrido G., Moreno E., Pérez R., Tania CrombetFuentes:scopusGangliosides, Ab1 and Ab2 antibodies. I. Towards a molecular dissection of an idiotype-anti-idiotype system
ArticleAbstract: This report is focused on the molecular basis for the interaction of a monoclonal antibody (mAb) andPalabras claves:Anti-idiotypic antibodies, H-CDR, N-Glycolyl-gangliosidesAutores:González M., López-Requena A., Mateo de Acosta C., Moreno E., Pérez R., Puchades Y., Santiago Nelson Vispo, Talavera A., Vázquez A.M.Fuentes:scopusBivalent binding by intermediate affinity of nimotuzumab: A contribution to explain antibody clinical profile
ArticleAbstract: Nimotuzumab is an EGFR-targeting antibody that has demonstrated encouraging clinical results in thePalabras claves:Affinity, Avidity, Cancer immunotherapy, eGFR, monoclonal antibodies, nimotuzumab, Tumor targetingAutores:Fernandez L.E., Garrido G., Gracia E., Iznaga N., Kerbel R.S., Pérez R., Rabasa A., Tania Crombet, Tikhomirov I.A., Yang E.Fuentes:scopus